New York State Common Retirement Fund Makes New $295,000 Investment in Indivior PLC (NASDAQ:INDV)

Key Points

• The New York State Common Retirement Fund acquired a new stake in Indivior PLC, purchasing 30,960 shares valued at approximately $295,000 during the first quarter.
• Indivior reported a quarterly earnings per share (EPS) of $0.41, surpassing the consensus estimate of $0.22, with total revenue of $266 million.
• Several analysts have given a buy rating to Indivior and set a price target ranging from $20 to $22, indicating positive investor sentiment about the stock's potential performance.

New York State Common Retirement Fund acquired a new stake in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,960 shares of the company's stock, valued at approximately $295,000.

A number of other institutional investors also recently modified their holdings of INDV. Rathbones Group PLC grew its holdings in shares of Indivior by 11.6% in the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock valued at $183,000 after acquiring an additional 1,483 shares in the last quarter. Two Sigma Investments LP grew its stake in Indivior by 2.1% during the fourth quarter. Two Sigma Investments LP now owns 110,880 shares of the company's stock valued at $1,378,000 after acquiring an additional 2,237 shares in the last quarter. Stifel Financial Corp raised its position in shares of Indivior by 24.0% in the fourth quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock worth $158,000 after buying an additional 2,450 shares in the last quarter. PDT Partners LLC increased its position in shares of Indivior by 4.7% in the fourth quarter. PDT Partners LLC now owns 57,520 shares of the company's stock worth $715,000 after purchasing an additional 2,596 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in Indivior in the fourth quarter valued at $36,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Stock Up 0.7%

NASDAQ:INDV traded up $0.12 during mid-day trading on Wednesday, reaching $17.40. 8,828,231 shares of the company's stock traded hands, compared to its average volume of 2,073,941. The company has a 50 day moving average price of $14.47 and a 200-day moving average price of $11.77. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $17.70.

Analyst Ratings Changes

Several research firms have weighed in on INDV. Wall Street Zen raised shares of Indivior from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Craig Hallum increased their target price on Indivior from $15.00 to $22.00 and gave the company a "buy" rating in a report on Monday, June 30th. Finally, Jefferies Financial Group initiated coverage on shares of Indivior in a report on Tuesday, July 22nd. They issued a "buy" rating and a $20.00 target price on the stock. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $17.75.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.